CX3CL1 and ovarian cancer: In a follow-up study, we will add more toxicity indicators of chemotherapy drugs to comprehensively evaluate the effect of CX3CL1/CX3CR1 gene polymorphisms on the clinical efficacy of carboplatin in patients with ovarian cancer.